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Abstract: Oxidative damage has been linked to a number of diseases. Oleuropein (OLE), a natural
occurring polyphenol from olive leaves (Olea europaea L.), is known to be a potent antioxidant
compound with inherent instability and compromised bioavailability. Therefore, in this work,
nanostructured lipid carriers (NLCs) were proposed for OLE encapsulation to protect and improve its
antioxidant efficacy. The lipid matrix, composed of olive oil and Precirol, was optimized prior to OLE
encapsulation. The characterization of the optimized oleuropein-loaded NLCs (NLC-OLE) showed a
mean size of 150 nm, a zeta potential of −21 mV, an encapsulation efficiency of 99.12%, sustained
release profile, and improved radical scavenging activity. The cellular in vitro assays demonstrated
the biocompatibility of the NLCs, which were found to improve and maintain OLE antioxidant
efficacy in the A549 and CuFi-1 lung epithelial cell lines, respectively. Overall, these findings suggest
a promising potential of NLC-OLE to further design a pulmonary formulation for OLE delivery in
lung epithelia.
Keywords: oleuropein; polyphenols; nanoparticle; natural antioxidant; nanotechnology; olive oil
1. Introduction
Reactive oxygen species (ROS) have an essential role in normal cell function and signaling.
However, their overproduction leads to an oxidative stress status that ultimately contributes to
the development of several pathological events such as inflammation, fibrosis, genotoxicity, and
carcinogenesis. As a result, oxidative stress has been linked to more than 50 diseases involving several
human organs [1–4]. Among them, the respiratory tract is one of the main sites for the presence of
prooxidant molecules. Moreover, clinical evidence suggests that many lung diseases are associated
with a reduced antioxidant defense, together with an increased accumulation of ROS [5]. Although
current strategies toward oxidative damage have been focused on the use of small ROS scavenger
drugs (i.e., Edaravone, N-acetylcysteine, Cerovive®) their toxicity, together with their low clinical
efficacy, has been discouraging [5,6]. Given this, natural antioxidants have emerged as alternative or
even complementary candidates with minimized toxicity.
Extracted from olive leaves, oleuropein (OLE) is widely known for its potent antioxidant efficacy
which, interestingly, seems to be the basis for its pleiotropic pharmacological activities: hypoglycemic [7],
antiviral [8], antimicrobial [9], platelet anti-aggregant [10], anticancer [11,12], hypolipidimic [13], and
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anti-inflammatory [14,15], among others. Even the European Medicines Agency (EMA) as well
as the European Food Safety Agency (EFSA) have made their own assessment reports about the
health-promoting properties of this natural compound in human health [16,17]. Despite its promising
properties, the therapeutic use of OLE is limited by its poor stability against environmental (light,
oxygen, temperature) and human biological conditions (pH, enzymes) [18], resulting in compromised
bioactivity, bioaccessibility, and bioavailability [19]. Along with these limitations, the lack of target
specificity hampers the therapeutic application of OLE.
In this context, micro and nanoencapsulation technologies have been proposed as promising
strategies [20]. Currently, some encapsulation methods for Olea europaea leaf extracts have been
described such as W/O nanoemulsions and W/O/W double emulsions [21–23], spray-drying [24,25],
formation of inclusion complexes with cyclodextrin [26], electrostatic extrusion [27], biopolymer
complexes/double emulsions [21], and liposomes [28]. However, they have some limitations such
as the use of organic solvents, tedious and time consuming manufacturing processes, high particle
sizes, and low yield (for spray drying). Furthermore, a low amount of OLE is normally encapsulated
in the final formulation (~1–2% w/w) and there is a lack of tests ensuring the preservation of OLE
antioxidant activity in biological systems. Given this scenario, lipid nanoencapsulation and particularly,
lipid nanostructured carriers (NLCs) offer special advantages: scale-up feasibility, long-term stability,
high drug loading, sustained release, good biocompatibility, biodegradable properties, and most
importantly, the increased local deposition of the drug [29–32]. Moreover, the lipid excipients used for
NLC formulation have documented biological anti-inflammatory effects in several disease models,
which might result in a synergistic effect with the encapsulated compound [33,34]. NLCs are made
up of a lipid core formed by a mixture of solid and liquid lipids stabilized by surfactants and offer
the possibility of incorporating both lipophilic and hydrophilic drugs [35]. The selection of the
encapsulating material is critical in the design of the nanoparticles [36]. In this work, Precirol and
olive oil were chosen to form the lipid core due to its efficacy in sustained release formulations and its
ability to reduce the possible cytotoxicity effect of residual surfactants that might be present in the final
nanoformulation, respectively [37].
Hence, the goal of this work was to elaborate OLE-loaded NLCs to modulate the antioxidant
activity of the encapsulated compound in lung epithelial cells. With the aim to obtain a nanoformulation
with suitable physico-chemical properties, a preformulation study was conducted varying the amount
of liquid and solid lipids of the nanoparticle matrix. The most promising nanoformulation was chosen
for the evaluation of OLE encapsulation, in vitro release profile, thermal behavior, and chemical
antioxidant activity. Finally, the biocompatibility of OLE-loaded NLCs as well as their cellular
antioxidant efficacy were investigated in three lung epithelial cell models.
2. Materials and Methods
2.1. Materials
2.1.1. Chemicals
Precirol® ATO 5 (glycerol distearate) was a kind gift from Gattefosé (Saint-Priest, France).
Polysorbate and Tween® 80 were purchased from Panreac Química (Castellar del Vallès, Barcelona,
Spain). Organic extra virgin olive oil was donated by Biosasun S.A. (Álava, Spain). Poloxamer 188
and 2,2-diphenyl-1-picrylhydrazyl (DPPH) were kindly provided by Merck (Darmstadt, Germany).
D-trehalose anhydrous was purchased from ACROS Organics™ (Geel, Belgium). OLE (>80%) was
donated by Nonaherbs Bio(Tech) (Xi’an, China). Ascorbic acid was purchased from Sigma-Aldrich
Chemicals (St. Louis, MO, USA). The ultrapure water was from a Milli-Q Water System. Other
chemicals were all analytical grade.
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2.1.2. Cell Culture Reagents
A549 (ATCC® CCL-185™), CuFi-1(ATCC® CRL-4013™) and NuLi-1 (ATCC® CRL-4011™) cells
were bought from the American Type Culture Collection (ATCC; Manassas, VA, USA). Roswell Park
Memorial Institute (RPMI) 1640 medium without phenol red, N-2-hydroxyethylpiperazine-N-2-ethane
sulfonic acid (HEPES), penicillin-streptomycin (PEST), inactivated fetal bovine serum (FBS), Dulbecco’s
Phosphate Buffered Saline (DPBS) and trypsin-EDTA (0.5%) without phenol red were purchased from
Gibco™ (Life Technologies, Madrid, Spain). Serum-free Bronchial Epithelial Growth Medium (BEGM
Bullet Kit; CC-3170) made of BEBM basal medium and SingleQuot additives; Airway Epithelial Cell
Basal Medium and Bronchial Epithelial Cell Growth Kit additives were purchased from Lonza (Clonetics,
Lonza, Walkersville Inc., Walkersville, MD, USA). Dimethyl sulfoxide (DMSO) was purchased form
Scharlau (Madrid, Spain). Human Placental Collagen Type IV (Sigma Cat. No. C-7521) and Cell
Counting Kit-8 (CCK-8) were bought from Sigma-Aldrich (Saint Louise, MO, USA). OxiSelect™Cellular
Antioxidant Cell Kit was bought from Quimigen (Madrid, Spain) to Cell Biolabs, Inc. (San Diego,
CA, USA).
2.2. Preparation of Nanostructured Lipid Carriers (NLC)
2.2.1. Blank-Nanostructured Lipid Carriers (NLCs)
Nanostructured lipid carriers, NLCs, were elaborated by the hot melt homogenization method
as previously described by our research group [38] with few modifications. Briefly, Precirol ATO® 5
(solid lipid; melting point: 56 ◦C) and olive oil (liquid at room temperature (RT)) were chosen to form
the lipid core. Several solid–liquid lipid proportions ranging from 10:90 to 90:10 were employed for
each batch manufacturing to study their effect in formulation parameters. This lipid phase was melted
5 ◦C above the solid lipid (Precirol ATO® 5) melting point until a clear and homogeneous phase was
obtained. The aqueous phase was prepared by dispersing 1.3% (w/v) of Tween® 80 and 0.66% (w/v) of
Poloxamer 188 in Milli-Q water and heating to the same temperature as the lipid phase. Straightaway,
the hot aqueous phase was added to the melted oily phase, and then sonicated for 30 s at 50 W (Branson
Sonifier 250, Danbury, CT, USA). The formed nanoemulsion was maintained under magnetic stirring
during 10 min at RT and stored for 2 h at 4 ◦C to allow the re-crystallization of the lipids and NLC
formation. Then, the particles were collected using a 100-kDa molecular weight cut-off centrifugal
filter unit (Amicon, “Ultracel-100k”, Millipore, Spain) at 2500 rpm for 10 min and washed three times
with MillliQ water. All of the nanoparticles prepared were freeze-dried for 36 h (Telstar Lyobeta
freeze-dryer, Terrasa, Spain). Prior to the lyophilization process of the resulting NLC suspension, a
solution of a cryoprotectant (trehalose (15% w/w)) was added to the collected nanoparticles.
2.2.2. Oleuropein (OLE)-Loaded NLCs (NLC-OLE)
From the developed formulations, the lipid matrix accomplished with the best physico-chemical
characteristics was selected for OLE encapsulation studies. OLE-loaded NLCs were prepared as
described above, but adding the corresponding volume of a saturated solution of OLE in purified water
(0.66 mg/mL). As OLE is hydrophilic and slightly thermosensitive, it was blended in the molten lipid
phase just prior to the addition of the aqueous phase and the following sonication process. The targeted
loading of OLE in NLCs were 30% (NLC-OLE30), 40% (NLC-OLE40), and 50% (NLC-OLE50) (w/w).
2.3. Characterization of Lipid Nanoparticles
2.3.1. Size and Zeta Potential
The mean particle size (Z-average diameter) was measured by dynamic light scattering (DLS) and
zeta potential was determined through Laser Doppler micro-electrophoresis (Malvern® Zetasizer Nano
ZS, Model Zen 3600; Malvern instruments Ltd., Malvern, UK). Prior to the measurements, nanoparticles
were dispersed in Milli-Q water (pH 5.6) at optimal intensity. For zeta potential, the measured
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electrophoretic mobility was converted into zeta potential through Smoluchowski approximation.
Each assay was performed in triplicate before and after the nanoparticles’ lyophilization and data are
presented as mean ± S.D.
2.3.2. Thermogravimetric Analysis
To assess the moisture content of freeze-dried nanoparticles, a thermogravimetric analysis was
performed (NETZSCH, STA 449 F1 Jupiter®, Barcelona, Spain). Samples (NLC-empty, NLC-OLE30,
NLC-OLE40, and NLC-OLE50) were heated from 25 to 200 ◦C at a heating rate of 5 ◦C/min under a
nitrogen atmosphere. Results are expressed as water content (%).
2.3.3. High-Performance Liquid Chromatography (HPLC) Method
Chromatographic analysis was performed using Alliance 2795 Waters equipment coupled to an
UV/Vis detector. Chromatographic separation was performed in a Zorbax Eclipse Plus® C18 column
(250 mm × 4.6 mm I.D.; 5.0 µm; Agilent Technologies, Wilmington, DE, USA) column. The mobile
phase consisted of acetonitrile:water (25:75 (v/v)) and pH was adjusted with ortophosphoric acid to 3.
The system was operated isocratically at a flow rate of 1.0 mL/min, and detection was performed at
230 nm. The retention time of OLE was 7.6 min at room temperature and the total run time of HPLC
analysis was 10 min. Prior to injection, samples (10 µL) were diluted in water and filtered (0.45 µm).
The method was validated in terms of linearity, accuracy, and specificity over the range of expected
concentrations. A linear correlation was observed in the concentration range of 6.20–420 µg/mL, with a
coefficient of determination r2 = 0.999 and RSD < 2%. The limit of detection and limit of quantification
were 0.2 µg/mL and 1.0 µg/mL, respectively. The method was specific for OLE and no interfering peaks
were observed near its retention time.
2.3.4. Encapsulation Efficiency (EE)
Encapsulation efficiency of OLE into NLCs was determined indirectly by measuring the free OLE
(non-encapsulated OLE) in the supernatant obtained after the filtration/centrifugation process. OLE
concentration was quantified by the explained HPLC method. Considering the initial amount of OLE
added to each formulation, the EE was calculated as:
EE (%) =
(
Total amount o f OLE−Amount o f f ree OLE
Total amount o f OLE
)
× 100, (1)
2.3.5. Microscopy Analysis
NLC surface characteristics and morphology were examined under transmission electron
microscopy (TEM, JEOL JEM-1400 Plus a 120 kV, Peabody, MA, USA). For this purpose, lyophilized
samples were suspended in Milli-Q water at an optimal concentration of 4 mg/mL and sonicated in a
water bath for one minute. Then, samples were placed on a carbon grid and treated with negative
staining uranyl acetate (2%) for particle visualization. Images were captured with a digital camera
sCMOS (Hamamatsu, Hawthorne, CA, USA).
2.3.6. In Vitro Drug Release Studies
In order to obtain qualitative and quantitative information on OLE release from NLCs, in vitro
drug release studies were conducted using Quix-Sep Micro Dialyzers (Membrane Filtration Products
Inc., Seguin, TX, USA) at 37 ◦C under magnetic stirring in phosphate buffer saline (PBS, pH 7.4). A
dialysis regenerated cellulose tubular membrane with a molecular weight cut-off (MWCO) between
12,000 and 14,000 Da was used. First, cellulose membranes were soaked in the dissolution medium
(PBS) for 12 h prior to its use to ensure thorough wetting of the membrane before placing it in a
Quix-Sep cell. To carry out this study, the NLC-OLE30, NLC-OLE40, and NLC-OLE50 suspensions
(25 mg/mL) were placed in the cell system, which was immersed in 30 mL of PBS preheated solution
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(pH 7.4) as the dissolution medium. At fixed time intervals up to 27 h, dissolution mediums were
removed from the incubation and replaced with new preheated PBS medium. Samples were kept at
4 ◦C until they were analyzed by HPLC (see Section 2.3.3). The release study was carried out under
proper sink conditions. Results were expressed as percentage of OLE released compared to the total
compound encapsulated in the nanoformulation. Experiments were run in triplicate for each point
of release kinetics. To further study OLE release kinetics and mechanism, the obtained cumulative
release data were computed with the DDsolver program and fitted to several kinetic models: zero
order, first order, Higuchi, Baker–Londslade, Hixson–Crowell, Hopfenger, and Korsmeyer–Peppas [39].
Regression coefficient (r2) was calculated to determine the best-fit model.
2.3.7. Differential Scanning Calorimetry (DSC)
The thermal behavior of the freeze dried NLCs was studied using differential scanning calorimetry
(DSC-50, Shimadzu, Japan). One to two milligrams of each sample was weighed and placed on an
aluminum pan and crimped. The samples were heated from 25 ◦C to 350 ◦C at the rate of 10 ◦C/min.
Pure solid lipid powder (Precirol® ATO5), OLE powder, pure solid surfactant (Poloxamer® 188),
and cryoprotectant (trehalose anhydrous) were also subjected to DSC analysis to gather additional
information. The crystallinity index (CI) of NLCs was calculated from the enthalpy of fusion using the
following equation:
CI (%) =
Enthalpy NLC [J/g]
Enthalpy solid lipid [J/g]
× 100, (2)
2.3.8. Radical Scavenging Activity Assessment by the 2,2-Diphenyl-1-Picrylhydrazyl (DPPH) Method
Radical scavenging activity of the nanoparticles was investigated spectrophotometrically,
analyzing their ability of scavenging DPPH radical [40]. Briefly, a solution of DPPH was prepared
with a concentration of 0.1 mM in absolute ethanol. Freeze-dried NLC-OLE50 was diluted in PBS
to obtain a final concentration of 1.25 mg/mL and they were left to release the drug for 24 h in the
same conditions as described in Section 2.3.6. Equivalent concentrations of OLE (0.2 mg/mL) and
NLC-empty (1.25 mg/mL) were also prepared in PBS and assayed in the same conditions. Ascorbic
acid (0.2 mg/mL) was used as the method control. A total of 500 µL of each sample was added to
3300 µL of DPPH-ethanol solution. The reaction mixture was incubated for 60 min protected from
light on a shaker at 37 ◦C. After that, the absorbance of the reaction solutions was recorded at 517 nm
by UV–Vis spectrophotometry (6705 UV/Vis Spectrophotometer JENWAY, Fisher Scientific SL, Madrid,
Spain). DPPH radical scavenging activity was calculated according to the following equation:
DPPH scavenging activity (%) =
(
Abs control−Abs sample
Abs control
)
× 100, (3)
where Abssample is the absorbance of the DPPH solution after reacting with the sample, and Abscontrol is
the absorbance of blank 0.1 mM DPPH solution. Ethanol was used as the blank. All measurements
were carried out in triplicate and the results are expressed as mean ± standard deviation.
2.4. Cell Experiments
2.4.1. Cell Culture
Human lung adenocarcinoma epithelial cells (A549) were grown and maintained in RPMI 1640
medium (pH 7.4) supplemented with 10% (v/v) inactivated FBS, 1% PEST, and 1% HEPES, without
phenol red and incubated at 90% humidity, 5% (v/v) CO2 atmosphere at 37 ◦C. Cells were allowed to
grow until 90% of confluence. Then, they were trypsinized (Trypsin-EDTA) and seeded in plates for
each experiment. Cystic fibrosis (CuFi-1) cell line, derived from a CF human bronchial epithelium
homozygous for the CFTR ∆F508 mutation, was grown and maintained in serum-free BEGM medium
at 37 ◦C, 90% humidity and 5% CO2. All culture-flasks were pre-coated with 60 µg/mL solution of
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Human Placental Collagen Type IV at least 18 h in advance, then air-dried and rinsed 2–3 times with
DPBS. Cells were allowed to grow until 80% of confluence, trypsinized (Trypsin-EDTA) and seeded in
plates for each experiment. Plates were also pre-treated with collagen as explained before. Human
normal bronchial epithelial (NuLi-1) cells were grown and maintained under the same conditions as
CuFi-1 cell line but in serum-free Airway Epithelial Cell Basal medium supplemented with Bronchial
Epithelial Cell Growth Kit additives.
2.4.2. Cell Viability Studies
Biocompatibility of empty nanoparticles (NLC-empty) and OLE-loaded nanoparticles
(NLC-OLE50) was evaluated in the A549, CuFi-1, and NuLi-1 cell lines. Each cell line was plated in
96-well microtiter plates at a density of 10,000 cells/well (A549) and 15,000 cells/well (NuLi-1, CuFi-1)
in a final volume of 100 µL of the corresponding cell medium. Cells were treated with NLC-OLE50
suspended in cell medium at concentrations ranging from 14.45 to 462.5 µM (in terms of encapsulated
OLE) and the equivalent amounts of NLC-empty, for 24 h at 37 ± 2 ◦C, 90% humidity, and 5% CO2.
Controls were set with dimethyl sulfoxide (DMSO) as the negative or death control, and medium
without formulation as the positive control. Free OLE was assayed for comparison. After 24 h of
incubation, cell viability was determined with the CCK-8. Cells were washed with sterile DPBS and
then 10% of CCK-8 in medium was added to each well and incubated in a wet chamber for 4 h at
37 ± 2 ◦C and 5% CO2. The resulting colored solution was quantified using a microplate reader
(Infinite1 200 PRO, Tecan, Männedorf, Switzerland). The spectrophotometric absorbance was measured
at 450/650 nm wavelength. Results were calculated in relation to the untreated cells (~100% viability)
and are expressed as the percent of cell viability ± standard deviation of the values collected from three
separate experiments performed in triplicate for each sample and each cell line.
2.4.3. Cellular Antioxidant Activity (CAA) Assay
Cellular ROS scavenging activity of NLC-OLE50 was measured using the OxiSelect™ Cellular
Antioxidant Activity Assay Kit in the A549, CuFi-1 and NuLi-1 cell lines. 2′,7′-dichlorodihydrofluorescin
diacetate (DCFH-DA) was used as the fluorogenic probe. Cells were seeded as previously explained in
clear bottom black polystyrene 96-well plates for 24 h. After that, all media was removed and washed
gently with DPBS w/o calcium and magnesium three times. Cells were then treated with OLE, both free
and nanoencapsulated, at the following concentrations: 115 µM, 231.2 µM, and 462.5 µM. After 24 h of
sample incubation at 37 ◦C, 90% humidity, and 5% CO2, the CAA assay was carried out. Briefly, wells
were washed with sterile DPBS and then 50 µL of DCFH-DA solution was added. Plates were incubated
for 60 min at 37 ◦C, 90% of humidity, and 5% CO2 in order to allow the cell-permeable fluorogenic
probe dye (DCFH-DA) to diffuse into the cells. After incubation, all solutions were removed and
wells were washed three times with DPBS. After addition of 100 µL of 2,2′-azobis (2-amidinopropane)
dihydrochloride (ABAP) solution, as the free radical initiator, fluorescence was read at 37 ◦C for 60 min
with 5 min intervals with the excitation wavelength 480 nm and emission wavelength of 530 nm.
Each plate included cell control wells (cells without any treatment), negative control wells (cells
pretreated only with DPBS and DCFH-DA), and positive control wells (cells pretreated with ABAP and
DCFH-DA). Quercetin was used as a standard in each experiment and was added following provider
instructions, just prior to the addition of DCFH-DA with the aim to validate the assay in the selected
cell models. Absence of green fluorescence in the studied samples was confirmed before the assay.
Each assay was carried out in triplicate for each cell line.
2.5. Statistical Analysis
All results were expressed as the mean ± standard deviation (SD) unless otherwise stated. All
statistical analyses were calculated using GraphPad Prism 6 Statistics software (San Diego, CA, USA)
and p < 0.05 was considered as significant. A multiple-sample and two-sample t test with unequal
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standard deviations was used to verify the significant difference between data in cellular antioxidant
and DPPH assays, respectively. For cell viability results, a two-way ANOVA was run.
3. Results and Discussion
3.1. Optimization and Physico-Chemical Characterization of Nanoparticles: Particle Size, Morphology, and
Zeta Potential
In the first step of this work, NLCs were prepared through the hot melt emulsification method
followed by ultrasonication (HME-Us), as previously described by our group [38]. The rationale for
using this technique relies on its versatility and easy scale-up. HME-Us have gained a lot of importance
after the Food and Drug Administration encouraged the use of continuous processes among the
pharmaceutical industry [41] and overcome most of the limitations offered by the conventional micro-
and nanoemulsification techniques. Avoidance of organic solvents, shorter and lower steps of the
process as well as the increased homogeneous spreading of the particles are some of the advantages
of this method [42,43]. Altogether, this makes HME-Us an industrially and environmentally friendly
technique that has largely been applied in the preparation of NLCs for multiple applications [44,45].
Unlike other lipid nanoparticles, the lipid core of NLCs is composed by the blend of a liquid
lipid and a solid lipid. The presence of this liquid lipid leads to a more amorphous matrix and a
less crystalline state of the carrier, which results in the accommodation of a higher number of drug
molecules compared to other lipid nanoformulations [45]. In this work, Precirol ATO 5 as the solid
lipid and olive oil as a natural liquid lipid were chosen for the lipid core formulation. Precirol ATO
5 has largely been used as a component of lipid matrix for sustained release formulations and has
proven to be effective in the formulation of NLCs for pulmonary delivery [30,38,46]. For liquid
lipids, the medium chain triglycerides, known under the brand name Miglyol 812, are the most
commonly employed. However, we selected olive oil as it is thought to reduce the possible cytotoxicity
effect of residual surfactants that might be present in the final nanoformulation [37]. Accordingly,
we employed an aqueous phase composed of the minimum amount of Tween 80 (1.3%, w/v) and
Poloxamer 188 (0.66%, w/v), which led to a nanoformulation with good physico-chemical stability
as previously demonstrated by our group [47,48]. Particle size and superficial charge are important
parameters in NLC development. Whilst particles sizes below 500 nm are generally thought to escape
from phagocytosis by macrophages [49], a negative superficial charge of around −20 mV is generally
correlated with good physical stability of the nanoparticle dispersion [50] as well as their attraction to
the positively charged proteins from damaged tissues [45,51]. Finally, aimed to improve NLC stability,
15% (w/w) of trehalose was chosen as a cryoprotectant as it was found to be the most suitable one for
the lyophilization process [38].
Therefore, the aim of this work was to obtain, through the HME-Us method, a NLC formulation
with the highest amount of olive oil as the liquid lipid and adequate physico-chemical characteristics. To
attain this purpose, various solid–liquid lipid ratios from 10:90 (formulation 1) to 90:10 (formulation 9)
were tested. Aqueous phase composition was always the same for all formulations. As summarized in
Table 1, it seemed that the higher the olive oil content, the smaller the particle size, which was then
confirmed by TEM micrographs (see Supplementary Materials). These results were in line with other
authors, who also reported a decrease in the particle size of NLCs when the liquid lipid amount was
increased [52–54]. Nevertheless, all formulations displayed adequate sizes between 100 and 200 nm.
Due to the dissociation of protons from the carboxylic groups of Precirol after dilution in deionized
water (pH 5.6), NLCs exerted a negative superficial charge, which was found to be around −20 mV for
all nanoformulations and thus all of them might have good physical stability [55,56]. In contrast, olive
oil content significantly affected the freeze-drying process of the NLCs. Particularly, we found that
the amount of olive oil in the lipid core should be ≤50% (w/w) to successfully achieve a lyophilized
product (Supplementary Materials, Section S1).
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Table 1. Physico-chemical characterization of the developed nanoformulations with different solid
lipid (Precirol ATO 5):liquid lipid (olive oil) ratio in the lipid core.
Formulation Code Lipid Core(Precirol:Olive Oil, %w/w) Size (nm) Z Potential (mV)
1 10:90 134.30 ± 5.23 −17.08 ± 1.20
2 20:80 129.62 ± 3.65 −17.03 ± 5.89
3 30:70 123.88 ± 2.43 −18.03 ± 4.01
4 40:60 121.73 ± 1.86 −17.66 ± 4.59
5 50:50 130.27 ± 4.55 −19.82 ± 2.84
6 60:40 141.69 ± 11.43 −21.64 ± 3.72
7 70:30 152.76 ± 27.17 −25.34 ± 4.52
8 80:20 148.50 ± 0.03 −26.16 ± 4.93
9 90:10 158.44 ± 7.57 −19.16 ± 2.52
Considering all the aforementioned, formulation 6, with an adequate particle size (~140 nm) and
superficial charge (~−22 mV) as well as the highest amount of olive oil in the lipid core (40%, w/w) that
allowed for a successful lyophilization process, was selected for the forthcoming loading studies.
3.2. Physico-Chemical Characterization of OLE-Loaded Nanoparticles
3.2.1. Particle Size, Z-Potential, Encapsulation Efficiency, Morphology, and Moisture
As shown in Figure 1A, OLE-loaded NLCs exhibited sizes of around 140 nm (NLC-OLE30), 120 nm
(NLC-OLE40), and 150 nm (NLC-OLE50). For the zeta potential, no significant differences were found
after OLE incorporation into the lipid matrix, indicating that physical stability of the nanoparticles was
not disturbed by OLE loading. With regard to the water content, similar low moisture values ranging
from 0.4% (NLC-OLE30) to 1.33% (NLC-OLE40) were found. As depicted by the TEM micrographs
(Figure 1B), OLE-loaded nanoparticles displayed a uniform and rounded shape. According to the
100 nm scale-bars in the images, the mean diameter was found to be less than 200 nm in all cases,
validating the results obtained with DLS techniques (Figure 1A). Finally, the entrapment efficiency
of OLE (Figure 1A) was above 95% in all cases, and thus, the developed NLCs were validated as an
adequate delivery system for future applications.
3.2.2. In Vitro Drug Release
Results from the performed in vitro release studies, at physiological pH and temperature (pH 7.4
and 37 ◦C, respectively), are reported in Figure 1C as the percentage of OLE released over time. A
sustained release of the olive polyphenol was detected in all cases up to 27 h, which might suggest
that OLE was protected inside the core of the lipid carries. For the NLC-OLE40 and NLC-OLE50
formulations, a total OLE-release of ~80% was found by the end of the study (27 h). However,
NLC-OLE30 showed a significantly lower percentage of released OLE (65% after 27 h). It is known that
the release profile of OLE could have a significant effect on its antioxidant and bioactive properties.
Therefore, aimed to ensure that the obtained release patterns of NLCs were sustained as well as
to describe the release mechanism of OLE from the developed NLC matrices, mathematical kinetic
models were applied to the experimental data obtained in the release assay (Table 2) [57,58]. The
regression coefficient value (r2) was used to choose the model that best fitted the data. In this
work, Korsmeyer–Peppas showed the highest r2 for all nanoparticle formulations with r2 = 0.977
(NLC-OLE30), r2 = 0.998 (NLC-OLE40), and r2 = 0.999 (NLC- OLE50), respectively. This type of release
has been reported before for some nanostructured lipid carriers [59–61]. In addition, the diffusional
exponent ‘n’ of the Korsmeyer–Peppas model also described the OLE release mechanism, which in
this case was in the range 0.46 to 0.59, indicating that OLE was released by an anomalous transport
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mechanism [58]. These results imply that probably a combination between erosion and diffusion
contributes to the release of the olive polyphenol from the lipid matrix of the nanoparticle.
Figure 1. Physico-chemical characterization of freeze-dried nanostructured lipid carriers: empty
(NLC-empty) and oleuropein (OLE) loaded, with a targeted OLE loading of 30% (NLC-OLE30), 40%
(NLC-OLE40) and 50% (NLC-OLE50) (w/w). (A) Particle size, Z potential, encapsulation efficiency,
total released OLE and moisture content of NLCs. (B) In vitro release of OLE from developed NLCs.
(C) TEM micrographs of OLE-loaded and empty nanoparticles. The scale bar indicates 100 nm.
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Table 2. Oleuropein (OLE) release parameters of different kinetic models.
Sample Kinetic Models
Zero Order First Order Higuchi Baker–Londslade Hixson–Crowel Hopfenger Korsmeyer–Peppas
r2 k r2 k r2 k r2 k r2 k r2 k r2 kp n
NLC-OLE30 −0.100 3.035 0.551 0.072 0.776 14.87 0.844 0.005 0.871 0.02 0.776 0 0.977 21.29 0.46
NLC-OLE40 −0.157 0 0.741 0.113 0.723 0.019 0.847 0.009 0.585 0.029 0.596 0.020 0.998 26.59 0.52
NLC-OLE50 0.150 3.680 0.836 0.108 0.840 17.89 0.947 0.009 0.708 0.028 0.733 0.022 0.999 20.61 0.59
r2, determination coefficient; k, release kinetic constant; kp, Korsmeyer–Peppas constant; n, diffusion release exponent.
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All in all, we demonstrated the sustained release of OLE via a nanocarrier delivery system that
could provide the opportunity to maintain prolonged targeted lung exposures to OLE and thus, longer
residence time in lung tissue.
3.2.3. DSC
Crystallization and thermal behavior of nanoparticles are important properties that determine
their utility as drug delivery systems [62,63]. Given this context, DSC thermograms and endothermic
events of the bulk solid lipid, bulk OLE, and NLCs (NLC-empty, NLC-OLE30, NLC-OLE40, and
NLC-OLE50) were analyzed. Results of the conducted thermal analysis are shown in Figure 2 and
Table 3.
 
 Figure 1. Physico-chemical characterization of OLE-loaded nanoparticles after freeze-drying. 
(a) Particle size, PDI, Z potential, encapsulation efficiency, total released oleuropein and moisture 
content of nanoparticles. (b) TEM micrographs of oleuropein loaded (NLC-OLE30, NLC-OLE40, 
NLC-OLE50) and empty nanoparticles (NLC-empty). (c) In vitro release of oleuropein from 
developed NLCs. 
 
Figure 2. DSC graphs of pure excipients (D-trehalose, Poloxamer 188, Precirol ATO 5, 
Oleuropein), developed nanoparticles with oleuropein (NLC-OLE30, NLC-OLE40, NLC-OLE50) 
and without oleuropein (NLC-empty). 
Figure 2. Differential scanning calorimetry (DSC) graphs of pure excipients (D-trehalose, Poloxamer
188, Precirol ATO 5, oleuropein (OLE), developed nanoparticles with OLE (NLC-OLE30, NLC-OLE40,
NLC-OLE50), and without OLE (NLC-empty).
Table 3. Thermal properties of Precirol and nanoparticles (NLC-empty, NLC-OLE30, NLC-OLE40, and
NLC-OLE50).
Sample Melting Point (◦C) Onset (◦C) Endset (◦C) Enthalpy (J/g) CI (%)
Precirol® ATO5 56.00 50.12 62.97 −150.56 100.00
NLC-empty 51.05 40.18 61.28 −90.21 59.92
NLC-OLE30 50.47 41.71 61.34 −56.22 37.34
NLC-OLE40 50.16 43.27 61.38 −57.15 37.96
NLC-OLE50 50.88 40.86 62.67 −63.09 41.90
CI (%): Crystallinity index.
Solid lipid Precirol® ATO 5 is known to have a melting range from 50 ◦C to 60 ◦C. As shown in
Figure 2, bulk Precirol® ATO 5 exhibits a sharp and single endothermic peak at 56.00 ◦C related to
its melting point. Since the diester fraction of the glyceride is apparently the only fraction present in
the bulk material, the main modification in which Precirol crystallizes should be the stable β-form,
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as occurs with most solid lipids. The DSC curve of bulk OLE (Figure 2) exerted a small but broad
endothermic event, ascribed to its melting point, at 64.70 ◦C, which ended up at around 103 ◦C, followed
by its decomposition. This result emphasizes the chemical stability of OLE under the nanoparticles’
manufacturing conditions. Poloxamer 188 showed a sharp melting endothermic peak at 56.69 ◦C and
trehalose anhydrous displayed its melting endotherm at 211.82 ◦C. For the thermograms of OLE-loaded
and unloaded NLCs, they showed two broadening endothermic peaks. The highest temperature
endotherms (around 56 ◦C) can be seen as a shoulder and are similar to the peak of Poloxamer 188.
The other endothermic event, around 50 ◦C, was at lower temperatures than that of the solid lipid. It
can be seen that these peaks were broader for NLC-empty. Therefore, there was a clear melting point
depression in all NLCs’ thermograms. This phenomenon is generally ascribed to the transformation
of the bulk solid lipid into its nanoparticle form as a result of their higher specific surface area or
the possible chemical interactions between solid lipid and liquid lipid/or surfactants/or drugs that
could take place during the nanoparticle production process and affect crystallization and result in
a lower melting enthalpy. Furthermore, the melting peak of OLE (64.7 ◦C) seemed to be absent in
the thermograms of the NLC-OLE formulations, suggesting that the encapsulated olive polyphenol
was in an amorphous state. As a result, we assumed that NLCs might offer a greater bioavailability
of OLE, as the melting point, an indicator of intermolecular attractive forces, is usually lower for
non-crystalline substances.
As expected, the addition of olive oil into the nanoparticle matrix clearly decreased the energy
required to melt the lipid (Table 3). On the other hand, Table 3 shows the enthalpy values for bulk
Precirol (−150.56 J/g), NLC-empty (−90.21 J/g), NLC-OLE30 −56.22 J/g), NLC-OLE40 (57.15 J/g), and
NLC-OLE50 (63.09 J/g). Furthermore, all nanoformulations showed a lower crystallinity index than
the bulk solid lipid. Interestingly, OLE-loaded NLCs displayed a greater decrease in both enthalpy and
CI values compared to NLC-empty. This energy reduction could be ascribed to the transformation
of the solid lipid (Precirol) into a less-ordered metastable β′-form, which leads to a disruption of
the crystalline structure and diminishes the CI, which could allow enough space to accommodate
OLE molecules.
Thus, the developed NLCs seemed to be a potential carrier for OLE and NLC-OLE50 was
selected to continue with the rest of the assays, since this formulation exhibited good physico-chemical
characteristics together with the highest OLE amount.
3.2.4. Radical Scavenging Activity by the DPPH Assay
The main bioactivity of OLE is related to its ability to eliminate free radicals and prevent lipid
peroxidation, which, in the end, contributes to alleviate the injuries caused by oxidative stress as
described elsewhere. Given this, the next step of this work was to verify that the antioxidant activity of
OLE was not disturbed by the nanoformulation process, and thus the radical scavenging activity of
NLC-OLE50 was assayed. As shown in Figure 3, free OLE had an antioxidant power of 55.33 ± 1.94%,
which was significantly enhanced by its incorporation in NLCs (61.22 ± 0.38%). These results could be
ascribed to the higher specific area of the nanoparticles for chemical quenching as well as the protection
of the polyphenol against external agents into the lipid matrix. Similarly, the encapsulation of other
natural compounds such as beta-carotene or quercetin into protein-based and polyvinyl alcohol–based
nanoparticles, respectively, and the co-loading of tocopherol and ascorbic acid in nutriosomes have
been shown to significantly improve their DPPH radical scavenging activity [64–66]. It is worth noting
that unloaded-NLCs did not exhibit any radical scavenging activity (−3.84 ± 1.79%) and thus, the
lipid excipients of the carrier had no influence on the antioxidant power of NLC-OLE50. Hence, we
demonstrated that the nanoencapsulation process through the hot-melt homogenization technique did
not decrease OLE activity but improved it.
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Figure 3. DPPH radical scavenging assay of free oleuropein (OLE), selected NLC-ole50 and its 
correspondent empty NLC formulation (NLC-empty). Results are expressed as mean % of DPPH 
radical scavenging activity compared to the control ± SD; n=3; *p<0.05, *** p<0.001. 
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Figure 3. 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay of NLC-OLE50 and equivalent
amounts of free OLE and NLC-empty. Results are expressed as mean % of DPPH radical scavenging
activity compared to the ontrol ± SD; n = 3; ** p < 0.05, *** p < 0.001.
3.3. Cell Experiments
In light of the characterization results, NLC-OLE50 seemed to be a promising carrier for OLE with
enhanced antioxidant activity and thus we continued to study its efficacy in lung epithelial cell models.
Several authors have reported micro- and nanoencapsulation methods for olive leaf extracts but to the
best of our knowledge, there is a lack of studies regarding the impact that the formulation process
could have on the bioactivity of this polyphenol in a biological system [22,23,52].
3.3.1. Cell Viability Studies
Nanotoxicology has gained special attention during the last decades. The main disadvantage of
nanoscale drug delivery systems is their potential cytotoxicity [44]. Generally, nanoparticle toxicity
is correlated with the type of excipients and organic solvents employed during the manufacturing
process that remain in the final formulation. In this work, we proposed NLCs made up with generally
recognized as safe (GRAS) excipients and the use of organic solvents was avoided during their
preparation. Moreover, the encapsulated natural compound is known to have low toxicity. Altogether,
they lead us to hypothesize that NLC-OLE50 will result in a highly biocompatible formulation with
minimum toxicity to the lung epithelium. Therefore, we aimed to prove our hypothesis and thereafter
selected the appropriate NLC concentration for cellular oxidative stress studies, the biocompatibility
of the formulations was assayed by the CCK-8 test in the A549, CuFi-1, and NuLi-1 cell lines as models
of pathological and healthy pulmonary epithelia (Figure 4).
Different concentrations of OLE ranging from 7.2 to 462.5 µM and its equivalent amount in NLCs
were tested after 24 h of incubation. Equivalent concentrations of empty NLCs were also assayed as
the control. Cell viability values >70% are considered as “no toxicity” [67] and thus, we assumed that
NLCs as well as OLE were biocompatible with the tested lung epithelial cell lines. It is worth noting
that NLC-empty did not shown any toxic effect, confirming the biocompatibility of the excipients of
the NLCs (Supplementary Materials, Section S2). This finding is in accordance with other reports
that demonstrated the good tolerability of lipid nanoparticles in lung epithelial cell lines [30,68,69].
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Considering these results, OLE concentrations from 115.6 to 462 µM and their equivalent amount in
NLC-OLE50 were chosen for the following antioxidant activity studies.
Figure 4. Effect of nanoencapsulated (NLC-OLE50) and free oleuropein (OLE) at different concentrations
on the viability of the A549, NuLi-1, and CuFi-1 cell lines among 24 h. The results are given as the
mean % of living cells compared to the control ± SD, n = 3. * p < 0.05, ** p < 0.01.
3.3.2. Antioxidant Activity of Nanostructured Lipid Carriers (NLCs) in Lung Epithelial Cells:
CAA Assay
The oxidative stress pathway has gained special attention as a novel target for the treatment of
a number of diseases. Particularly within the lungs, oxidative stress has been correlated with lung
cancerogenesis mechanisms as well as cystic fibrosis progression among others, in which natural
antioxidants have been proposed as promising candidates [1,3–6]. Our optimized NLC-OLE50 had
been demonstrated, by chemical analysis, to improve the radical scavenging power of OLE. Moreover,
the size of our NLCs fell within the favorable range (100–200 nm) for an efficient cellular uptake, most
likely to be taken up through the cell membranes by endocytosis mechanisms [70,71]. Beyond this, we
have demonstrated a sustained release of the olive polyphenol from the lipid matrix within 24 h and
thus, we assumed that OLE, which is protected inside the lipid core, might be progressively released to
the cell, avoiding its rapid degradation and metabolism to other polyphenols (i.e., hydroxytyrosol,
tyrosol, oleuropein aglycone), thus preserving or even improving its efficacy against oxidative stress.
Altogether, this led us to hypothesize that NLC-OLE50 could be a promising carrier for OLE toward
oxidative stress related injuries in lung epithelia. However, the lack of in vivo data about OLE efficacy
in the lungs encouraged us to conduct a preliminary cell-based study to further confirm its effectiveness
in lung cells.
Given this scenario, the radical scavenging activity of NLC-OLE50 and OLE was measured in
ABAP-stressed A549, CuFi-1, and NuLi-1 as human-lung epithelial cell models, after 24 h of exposure
to the mentioned treatments. The morphology of the cells was always checked to ensure that the
induced oxidative damage did not cause cell death. Obtained results are displayed in Figure 5 as the
percentage of intracellular ROS levels compared to the positive control (~100% of ROS levels).
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Figure 5. Antioxidant activity of free oleuropein (OLE), encapsulated OLE (NLC-OLE50), and empty
nanoparticles (NLC-empty) in ABAP-stressed A549 (A), CuFi-1 (B), and NuLi-1 (C) cells. The mean
percentages of DCF fluorescence, as a measure of oxidative stress, are shown in relation to the positive
control (set to 100%). Results shown are means ± SEM of at least three independent experiments.
* p < 0.05, ** p < 0.01, *** p < 0.001 vs. positive control; # p < 0.05, ## p < 0.01, ### p < 0.001 vs. free OLE.
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Following our hypothesis, NLC-OLE50 clearly alleviated the oxidative stress status of A549 cells,
which was found to be dose-dependent (Figure 5A). It should be noted that non-encapsulated OLE
was only able to reduce ROS at the highest concentration tested (462.5 µM, p < 0.001) and, most
importantly, it exerted prooxidant effects at 115 µM (p < 0.05) and 231 µM (p < 0.01). This result is
in line with other authors who have demonstrated the prooxidant activity of OLE in some specific
cancer cell lines of human breast cancer [72,73] and hepatocarcinoma [74]. However, there is still a
lack of studies to further justify these findings. Therefore, we assumed that NLC-OLE50 significantly
enhanced the antioxidant power of OLE in the A549 cell line, and this finding might be ascribed to a
better permeability across cell membranes of the NLCs as well as their well-known higher uptake by
the cellular model [65,75,76]. For the CuFi-1 human cells, NLC-OLE50 was demonstrated to preserve
the moderate antioxidant power of OLE. Similarly, Hatahet et al. showed that the encapsulation of
quercetin into NLCs did not improve its antioxidant activity, but preserved it in acute monocytic
leukemia cells [77]. Evidence suggests that the misfolded CFTR protein can be modulated through
antioxidant and prooxidant effects in cell environment and thus, we assumed that NLC-OLE50 and
OLE might have interacted with the misfolded CFTR protein in CuFi-1 cells [1,78,79]. Unexpectedly,
with regard to healthy epithelial cells (NuLi-1), neither free nor encapsulated OLE exerted any effect
against ABAP produced peroxyl radical reaction, which could be ascribed to the inherent capacity of
normal airways to cope with oxidative stress by themselves [79].
Given the aforementioned, the cellular antioxidant effects of NLC-OLE50 clearly depend on
the studied cell line, which could be correlated with their different cellular uptake mechanisms.
Nanoparticles are generally thought to be internalized through endocytosis mechanisms (i.e.,
phagocytosis, pinocytosis, clathrin-mediated, and caveolae/raft-mediated transports). Previous studies
from our group demonstrated that the composition of the nanoparticles together with the type of cell
can determine the predominant endocytosis mechanisms for their uptake and intracellular distribution,
which ultimately affect the delivery of the active compound and the efficacy of the formulation [80–82].
These findings are in line with other authors who have demonstrated that the uptake of nanospheres
by A549 cells could occur by clathrin-mediated endocytosis (PLGA and chitosan-PLGA nanospheres,
100 nm) as well as by the caveolae/raft-dependent transport (wheat germ agglutinin-conjugated PLGA
nanospheres, 200 nm) [83]. On the other hand, evidence also suggests that depending on the size,
shape, and surface charge of the nanoparticles, a particular cellular internalization route may be
preferred over others. From the scarce data available about nanoparticle efficacy in cystic fibrosis
cells, we found that authors have given special attention to the surface chemistry of the NLCs as
an important influence factor for their cellular uptake and thus, one possibility of enhancing our
NLC activity in CuFi-1 cells could be the modification of their superficial charge. However, whilst
some authors have suggested that decreasing the surface charge of nanoparticles up to −50 mV could
enhance their cellular uptake (CuFi-1 cells) [84], others have postulated that positive superficial charge
is required to promote their internalization (CFBE41o-cells) [85] and thus it is highlighted again that
special attention should be given not only to particle superficial charge, but also to the cell line and
its predominant endocytosis mechanisms of transport. Similarly, the A549 cells were also shown to
be more sensitive to OLE activity compared to the CuFi-1 and NuLi-1 cells. Since passive diffusion
through cellular membranes is almost similar for all cells, scientific evidence suggests that differences
in the active membrane transports are likely to be responsible for the differences observed in the
CAA results between cell lines. Accordingly, the glucose moiety of OLE is known to interact with the
membrane glucose transporter proteins (GLUT), allowing its diffusion into the cells. It is known that
GUT is overexpressed in A549 cell membranes and thus we assumed that a higher uptake of OLE
could have occurred in these cells, which ultimately might have led to a more pronounced intracellular
antioxidant effect compared to the other cell lines [86]. A similar phenomenon has been found for the
natural flavonoids quercetin, catechin, and epicatechin, which had superior antioxidant activities in
Caco-2 compared to the HepG2 cell lines, probably due to a higher accumulation in Caco-2 cells [87,88].
However, little data are available about the role of transporters in cellular accumulation and evidence
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for individual phenolic compounds remains at a basic level. Finally, it should be noted that NLC-empty
did not show any effect in the tested cell lines with the exception of A549 cells, which at the highest
tested concentration seemed to increase ROS generation but without toxic effects.
All in all, the preserved antioxidant activity of OLE in NLCs holds great promise for transporting
this natural polyphenol to the lung epithelia but further studies should be conducted to elucidate their
internalization mechanism and intracellular trafficking processes in the proposed cells, which can be
modulated by optimizing the formulations toward more efficient nanocarriers.
4. Conclusions
Whilst a number of preclinical data have revealed the therapeutic properties of olive polyphenols
as plant extracts or pure synthetic molecules, scarce studies are available concerning isolated OLE
and more specifically, naturally obtained OLE. In this work, OLE, a natural antioxidant with poor
stability and compromised bioavailability, was successfully formulated in highly biocompatible NLCs.
Optimized nanoparticles exhibited a mean size of 150 nm, demonstrated to be effective in loading up to
50% (w/w) of OLE with an encapsulation efficiency of 99.12%, a sustained release kinetic from the lipid
core and enhanced antioxidant power was proven in the DPPH assay. Moreover, the rapid and simple
proposed formulation process avoided the use of organic solvents and OLE loading was significantly
higher compared to the other reported methods [25,27,28,89]. NLCs were found to be biocompatible in
three lung epithelial cell lines, indicating their safety for lung administration. Interestingly, NLCs were
shown to enhance and maintain the OLE protection effect against oxidative stress in lung cancer and
cystic fibrosis cells, respectively, and thus, they could hold great promise for transporting this natural
polyphenol to the lung epithelial cells. Nonetheless, further formulation studies should be conducted
to obtain an adequate final formulation for pulmonary administration of NLC-OLE50 (i.e., dry powder
for inhalation) [90–92].
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/5/429/s1,
Section S1: Nanoparticle morphology and success in freeze-drying process of blank nanoparticles. Section S2: Cell
viability assay of NLC-empty.
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